Autologous fecal sample for use in the treatment of microbial dysbiosis
US11045501B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2018 |
| Grant date | Jun 29, 2021 |
| Priority date | — |
| Expiry date | Jan 19, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the use of autologous fecal samples obtained from a subject for use in prevention and/or treatment of microbial dysbiosis in the gastrointestinal tract in said subject and to related pharmaceutical compositions for oral administration. The disclosed autologous fecal samples are useful for treatment of microbial dysbiosis in the gastrointestinal tract associated with medical treatment and/or various indications, including chronic disease and infectious disease, for example Clostridium difficile infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.